These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 15030263)

  • 1. Pharmacological profile and clinical use of moexipril.
    Chrysant SG; Chrysant GS
    Expert Rev Cardiovasc Ther; 2003 Sep; 1(3):345-52. PubMed ID: 15030263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological and clinical profile of moexipril: a concise review.
    Chrysant SG; Chrysant GS
    J Clin Pharmacol; 2004 Aug; 44(8):827-36. PubMed ID: 15286086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride.
    Friehe H; Ney P
    Arzneimittelforschung; 1997 Feb; 47(2):132-44. PubMed ID: 9079232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moexipril. A review of its use in the management of essential hypertension.
    Brogden RN; Wiseman LR
    Drugs; 1998 Jun; 55(6):845-60. PubMed ID: 9617599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril.
    Edling O; Bao G; Feelisch M; Unger T; Gohlke P
    J Pharmacol Exp Ther; 1995 Nov; 275(2):854-63. PubMed ID: 7473177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety and efficacy of moexipril alone and in combination with hydrochlorothiazide in elderly patients with hypertension.
    White WB; Stimpel M
    J Hum Hypertens; 1995 Nov; 9(11):879-84. PubMed ID: 8583466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Angiotensin converting enzyme inhibitor moexipril in the treatment of arterial hypertension. Possibilities of moexipril in the treatment of postmenopausal women].
    Ostroumova OD; Paukov SV; Frolova LI
    Kardiologiia; 2006; 46(11):92-8. PubMed ID: 17159885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the antihypertensive effectiveness of a combination of moexipril or sustained-release verapamil with low-dose hydrochlorothiazide.
    Chrysant SG; Stimpel M
    J Clin Pharmacol; 1996 Aug; 36(8):701-6. PubMed ID: 8877673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of moexipril, a new ACE inhibitor, to verapamil-SR as add-on therapy to low dose hydrochlorothiazide in hypertensive patients.
    Chrysant SG; Fox AA; Stimpel M
    Am J Hypertens; 1995 Apr; 8(4 Pt 1):418-21. PubMed ID: 7619356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide.
    Hutt V; Michaelis K; Verbesselt R; De Schepper PJ; Salomon P; Bonn R; Cawello W; Angehrn JC
    Eur J Clin Pharmacol; 1996; 51(3-4):339-44. PubMed ID: 9010710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control.
    Pines A; Fisman EZ
    Am J Cardiovasc Drugs; 2003; 3(5):351-60. PubMed ID: 14728069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of the new angiotensin-converting enzyme inhibitor moexipril on the circadian rhythms of arterial pressure in hypertension patients].
    Ol'binskaia LI; Andrushchishina TB
    Ter Arkh; 1997; 69(3):58-61. PubMed ID: 9229835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moexipril and left ventricular hypertrophy.
    Chrysant GS; Nguyen PK
    Vasc Health Risk Manag; 2007; 3(1):23-30. PubMed ID: 17583172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moexipril versus captopril in patients with mild to moderate hypertension.
    Stimpel M; Koch B; Jansen T; Fox A; Loh I
    J Cardiovasc Pharmacol; 1996 Dec; 28(6):769-73. PubMed ID: 8961074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the duration of action of angiotensin converting enzyme inhibitors affect their safety and adverse effects?
    Frank GJ
    J Hypertens Suppl; 1989 Sep; 7(5):S17-22. PubMed ID: 2553900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of antihypertensive therapy on postmenopausal osteoporosis: effects of the angiotensin converting enzyme inhibitor moexipril, 17beta-estradiol and their combination on the ovariectomy-induced cancellous bone loss in young rats.
    Stimpel M; Jee WS; Ma Y; Yamamoto N; Chen Y
    J Hypertens; 1995 Dec; 13(12 Pt 2):1852-6. PubMed ID: 8903666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moexipril shows a long duration of action related to an extended pharmacokinetic half-life and prolonged ACE inhibition.
    Cawello W; Boekens H; Waitzinger J; Miller U
    Int J Clin Pharmacol Ther; 2002 Jan; 40(1):9-17. PubMed ID: 11837383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term efficacy and safety of moexipril in the treatment of hypertension.
    White WB; Fox AA; Stimpel M
    J Hum Hypertens; 1994 Dec; 8(12):917-21. PubMed ID: 7884791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moexipril: another ACE inhibitor for hypertension.
    Med Lett Drugs Ther; 1995 Sep; 37(956):75-6. PubMed ID: 7637658
    [No Abstract]   [Full Text] [Related]  

  • 20. Moexipril in the treatment of mild to moderate essential hypertension: comparison with sustained-release verapamil.
    Abernethy DR; Fox AA; Stimpel M
    J Clin Pharmacol; 1995 Aug; 35(8):794-9. PubMed ID: 8522636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.